VEXAS Syndrome for the laboratory physician: a case report

• by Chaoying Chen, Miaomiao Chen, Tieqiao Chen, Yong Chen, Lingzhi Liu, Yixi Zhu, Xiaoming Yi, Shuguang He

• May 6, 2026

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to explore advances in scaling cell and gene therapies

• May 6, 2026

• 1 min

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

• by Julia Cipriano

• May 5, 2026

• 15 min

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

• by Matthew Stenger

• May 5, 2026

• 2 min